Stockreport

Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma

IMMUNE DESIGN CORP COMMON STOCK  (IMDZ) 
Last immune design corp common stock earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.immunedesign.com/investor-relations
PDF - G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Cali [Read more]